Poor correlation between T-cell activation assays and HLA-DR binding prediction algorithms in an immunogenic fragment of Pseudomonas exotoxin A

Journal of Immunological Methods

Volumn 425, Issue , 2015, Pages 10-20

  Mazor, Ronit ^a   Tai, Chin Hsien ^a   Lee, Byungkook ^a   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

HLA binding algorithm; HLA binding prediction; Immunogenicity; MHC alleles; T cell activation; T cell epitope

Indexed keywords

BACTERIAL PROTEIN; EPITOPE; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE; PROTEIN PE38; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS EXOTOXIN A; UNCLASSIFIED DRUG; BACTERIAL TOXIN; EXOTOXIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BINDING; TOXA PROTEIN, PSEUDOMONAS AERUGINOSA; VIRULENCE FACTOR;

ALGORITHM; ALLELE; AMINO ACID SEQUENCE; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CORRELATION ANALYSIS; EPITOPE MAPPING; GENE FREQUENCY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; T LYMPHOCYTE ACTIVATION; ANTIBODY PRODUCTION; BINDING SITE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MOLECULAR GENETICS; PSEUDOMONAS; T LYMPHOCYTE;

ADP RIBOSE TRANSFERASES; ALGORITHMS; AMINO ACID SEQUENCE; ANTIBODY FORMATION; BACTERIAL TOXINS; BINDING SITES; EPITOPES, T-LYMPHOCYTE; EXOTOXINS; HLA-DR ANTIGENS; HUMANS; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN BINDING; PSEUDOMONAS; T-LYMPHOCYTES; VIRULENCE FACTORS;

EID: 84943659439     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2015.06.003     Document Type: Article

References (57)

1. Abdel-Hady K.M., Gutierrez A.H., Terry F., Desrosiers J., De Groot A.S., Azzazy H.M. Identification and retrospective validation of T-cell epitopes in the hepatitis C virus genotype 4 proteome: an accelerated approach toward epitope-driven vaccine development. Hum. Vaccin. Immunother. 2014, 10:2366.
2. Anderson R.P., Jabri B. Vaccine against autoimmune disease: antigen-specific immunotherapy. Curr. Opin. Immunol. 2013, 25:410.
3. Arons E., Adams S., Venzon D.J., Pastan I., Kreitman R.J. Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome. Br. J. Haematol. 2014, 166:729.
4. Baker M.P., Reynolds H.M., Lumicisi B., Bryson C.J. Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self/nonself 2010, 1:314.
5. Bunce M., O'Neill C.M., Barnardo M.C., Krausa P., Browning M.J., Morris P.J., Welsh K.I. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 1995, 46:355.
6. Cantor J.R., Yoo T.H., Dixit A., Iverson B.L., Forsthuber T.G., Georgiou G. Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:1272.
7. Cohen T., Moise L., Ardito M., Martin W., De Groot A.S. A method for individualizing the prediction of immunogenicity of protein vaccines and biologic therapeutics: individualized T cell epitope measure (iTEM). J. Biomed. Biotechnol. 2010, 2010:961752. 10.1155/2010/961752.
8. Delluc S., Ravot G., Maillere B. Quantitative analysis of the CD4 T-cell repertoire specific to therapeutic antibodies in healthy donors. FASEB J. 2011, 25:2040.
9. Fonseca S.G., Coutinho-Silva A., Fonseca L.A., Segurado A.C., Moraes S.L., Rodrigues H., Hammer J., Kallas E.G., Sidney J., Sette A., Kalil J., Cunha-Neto E. Identification of novel consensus CD4 T-cell epitopes from clade B HIV-1 whole genome that are frequently recognized by HIV-1 infected patients. Aids 2006, 20:2263.
10. Gonzalez-Galarza F.F., Christmas S., Middleton D., Jones A.R. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res. 2011, 39:D913.
11. Greenbaum J., Sidney J., Chung J., Brander C., Peters B., Sette A. Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes. Immunogenetics 2011, 63:325.
12. Hanley J.A., McNeil B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982, 143:29.
13. + T-cell epitopes 2008, 56. (United States). L. MedImmune (Ed.).
14. Harding F.A., Liu A.D., Stickler M., Razo O.J., Chin R., Faravashi N., Viola W., Graycar T., Yeung V.P., Aehle W., Meijer D., Wong S., Rashid M.H., Valdes A.M., Schellenberger V. A beta-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy. Mol. Cancer Ther. 2005, 4:1791.
15. Hassan R., Bullock S., Premkumar A., Kreitman R.J., Kindler H., Willingham M.C., Pastan I. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin. Cancer Res. 2007, 13:5144.
16. Hassan R., Miller A.C., Sharon E., Thomas A., Reynolds J.C., Ling A., Kreitman R.J., Miettinen M.M., Steinberg S.M., Fowler D.H., Pastan I. Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci. Transl. Med. 2013, 5:208ra147.
17. Iwai L.K., Yoshida M., Sidney J., Shikanai-Yasuda M.A., Goldberg A.C., Juliano M.A., Hammer J., Juliano L., Sette A., Kalil J., Travassos L.R., Cunha-Neto E. In silico prediction of peptides binding to multiple HLA-DR molecules accurately identifies immunodominant epitopes from gp43 of Paracoccidioides brasiliensis frequently recognized in primary peripheral blood mononuclear cell responses from sensitized individuals. Mol. Med. 2003, 9:209.
18. Jawa V., Cousens L.P., Awwad M., Wakshull E., Kropshofer H., De Groot A.S. T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation. Clin. Immunol. 2013, 149:534.
19. Juhasz F., Kozma L., Stenszky V., Gyory F., Luckas G., Farid N.R. Well differentiated thyroid carcinoma is associated with human lymphocyte antigen D-related 11 in Eastern Hungarians: a case of changing circumstances. Cancer 2005, 104:1603.
20. King C., Garza E.N., Mazor R., Linehan J.L., Pastan I., Pepper M., Baker D. Removing T-cell epitopes with computational protein design. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:8577.
21. Koren E., De Groot A.S., Jawa V., Beck K.D., Boone T., Rivera D., Li L., Mytych D., Koscec M., Weeraratne D., Swanson S., Martin W. Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. Clin. Immunol. 2007, 124:26.
22. Kreitman R.J., Wilson W.H., White J.D., Stetler-Stevenson M., Jaffe E.S., Giardina S., Waldmann T.A., Pastan I. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2000, 18:1622.
23. Kreitman R.J., Hassan R., Fitzgerald D.J., Pastan I. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin. Cancer Res. 2009, 15:5274.
24. Kreitman R.J., Tallman M.S., Robak T., Coutre S., Wilson W.H., Stetler-Stevenson M., Fitzgerald D.J., Lechleider R., Pastan I. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J. Clin. Oncol. 2012, 30:1822.
25. Kubler K., Arndt P.F., Wardelmann E., Krebs D., Kuhn W., van der Ven K. HLA-class II haplotype associations with ovarian cancer. Int. J. Cancer 2006, 119:2980.
26. Li X., Yang H.W., Chen H., Wu J., Liu Y., Wei J.F. In silico prediction of T and B cell epitopes of Der f 25 in Dermatophagoides farinae. Int. J. Genomics 2014, 2014:483905.
27. Marshall K.W., Liu A.F., Canales J., Perahia B., Jorgensen B., Gantzos R.D., Aguilar B., Devaux B., Rothbard J.B. Role of the polymorphic residues in HLA-DR molecules in allele-specific binding of peptide ligands. J. Immunol. 1994, 152:4946.
28. Mazor R., Vassall A.N., Eberle J.A., Beers R., Weldon J.E., Venzon D.J., Tsang K.Y., Benhar I., Pastan I. Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E3597.
29. Mazor R., Eberle J.A., Hu X., Vassall A.N., Onda M., Beers R., Lee E.C., Kreitman R.J., Lee B., Baker D., King C., Hassan R., Benhar I., Pastan I. Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:8571.
30. McGinnis M.D., Conrad M.P., Bouwens A.G., Tilanus M.G., Kronick M.N. Automated, solid-phase sequencing of DRB region genes using T7 sequencing chemistry and dye-labeled primers. Tissue Antigens 1995, 46:173.
31. McMurry J.A., Kimball S., Lee J.H., Rivera D., Martin W., Weiner D.B., Kutzler M., Sherman D.R., Kornfeld H., De Groot A.S. Epitope-driven TB vaccine development: a streamlined approach using immuno-informatics, ELISpot assays, and HLA transgenic mice. Curr. Mol. Med. 2007, 7:351.
32. Moise L., Song C., Martin W.D., Tassone R., De Groot A.S., Scott D.W. Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo. Clin. Immunol. 2012, 142:320.
33. Nielsen M., Lund O. NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinf. 2009, 10:296.
34. Nielsen M., Lundegaard C., Lund O. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinf. 2007, 8:238.
35. Nielsen M., Lundegaard C., Blicher T., Peters B., Sette A., Justesen S., Buus S., Lund O. Quantitative predictions of peptide binding to any HLA-DR molecule of known sequence: NetMHCIIpan. PLoS Comput. Biol. 2008, 4:e1000107.
36. Oseroff C., Sidney J., Kotturi M.F., Kolla R., Alam R., Broide D.H., Wasserman S.I., Weiskopf D., McKinney D.M., Chung J.L., Petersen A., Grey H., Peters B., Sette A. Molecular determinants of T cell epitope recognition to the common Timothy grass allergen. J. Immunol. 2010, 185:943.
37. Oseroff C., Sidney J., Vita R., Tripple V., McKinney D.M., Southwood S., Brodie T.M., Sallusto F., Grey H., Alam R., Broide D., Greenbaum J.A., Kolla R., Peters B., Sette A. T cell responses to known allergen proteins are differently polarized and account for a variable fraction of total response to allergen extracts. J. Immunol. 2012, 189:1800.
38. Paul W.E., Zhu J. How are T(H)2-type immune responses initiated and amplified?. Nat. Rev. Immunol. 2010, 10:225.
39. Paul S., Kolla R.V., Sidney J., Weiskopf D., Fleri W., Kim Y., Peters B., Sette A. Evaluating the immunogenicity of protein drugs by applying in vitro MHC binding data and the immune epitope database and analysis resource. Clin. Dev. Immunol. 2013, 2013:467852.
40. Paul S., Lindestam Arlehamn C.S., Scriba T.J., Dillon M.B., Oseroff C., Hinz D., McKinney D.M., Carrasco Pro S., Sidney J., Peters B., Sette A. Development and validation of a broad scheme for prediction of HLA class II restricted T cell epitopes. J. Immunol. Methods 2015, 422:28-34.
41. Salvat R.S., Parker A.S., Guilliams A., Choi Y., Bailey-Kellogg C., Griswold K.E. Computationally driven deletion of broadly distributed T cell epitopes in a biotherapeutic candidate. Cell. Mol. Life Sci. 2014, 71:4869.
42. Salvat R.S., Choi Y., Bishop A., Bailey-Kellogg C., Griswold K.E. Protein deimmunization via structure-based design enables efficient epitope deletion at high mutational loads. Biotechnol. Bioeng. 2015, 10.1002/bit.25554.
43. Sbai H., Mehta A., DeGroot A.S. Use of T cell epitopes for vaccine development. Current drug targets. Infect. Disord. 2001, 1:303.
44. Schulten V., Greenbaum J.A., Hauser M., McKinney D.M., Sidney J., Kolla R., Lindestam Arlehamn C.S., Oseroff C., Alam R., Broide D.H., Ferreira F., Grey H.M., Sette A., Peters B. Previously undescribed grass pollen antigens are the major inducers of T helper 2 cytokine-producing T cells in allergic individuals. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:3459.
45. + T cell responses to an inactivated flavivirus vaccine and infection: correlation with structure and epitope prediction. J. Virol. 2014, 88:7828.
46. Sette A., Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity 2010, 33:530.
47. Stevanovic S. Identification of tumour-associated T-cell epitopes for vaccine development. Nat. Rev. Cancer 2002, 2:514.
48. Sturniolo T., Bono E., Ding J., Raddrizzani L., Tuereci O., Sahin U., Braxenthaler M., Gallazzi F., Protti M.P., Sinigaglia F., Hammer J. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat. Biotechnol. 1999, 17:555.
49. Swain S.L., McKinstry K.K., Strutt T.M. Expanding roles for CD4(+) T cells in immunity to viruses. Nat. Rev. Immunol. 2012, 12:136.
50. Tangri S., Mothe B.R., Eisenbraun J., Sidney J., Southwood S., Briggs K., Zinckgraf J., Bilsel P., Newman M., Chesnut R., Licalsi C., Sette A. Rationally engineered therapeutic proteins with reduced immunogenicity. J. Immunol. 2005, 174:3187.
51. Tassignon J., Burny W., Dahmani S., Zhou L., Stordeur P., Byl B., De Groote D. Monitoring of cellular responses after vaccination against tetanus toxoid: comparison of the measurement of IFN-gamma production by ELISA, ELISPOT, flow cytometry and real-time PCR. J. Immunol. Methods 2005, 305:188.
52. Trowsdale J., Young J.A., Kelly A.P., Austin P.J., Carson S., Meunier H., So A., Erlich H.A., Spielman R.S., Bodmer J., Bodmer F.E. Structure, sequence and polymorphism in the HLA-D region. Immunol. Rev. 1985, 85:5.
53. Wang P., Sidney J., Dow C., Mothe B., Sette A., Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput. Biol. 2008, 4:e1000048.
54. Wang P., Sidney J., Kim Y., Sette A., Lund O., Nielsen M., Peters B. Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinf. 2010, 11:568.
55. Wilkins M.R., Gasteiger E., Bairoch A., Sanchez J.C., Williams K.L., Appel R.D., Hochstrasser D.F. Protein identification and analysis tools in the ExPASy server. Methods Mol. Biol. 1999, 112:531.
56. Zhang Q., Wang P., Kim Y., Haste-Andersen P., Beaver J., Bourne P.E., Bui H.H., Buus S., Frankild S., Greenbaum J., Lund O., Lundegaard C., Nielsen M., Ponomarenko J., Sette A., Zhu Z., Peters B. Immune epitope database analysis resource (IEDB-AR). Nucleic Acids Res. 2008, 36:W513.
57. Zhu J., Paul W.E. CD4 T cells: fates, functions, and faults. Blood 2008, 112:1557.